FIELD: medicine; pharmaceuticals.
SUBSTANCE: stable pharmaceutical composition containing the required protein, sorbitol and polyethylene glycol (PEG). Sorbitol and protein are present in molar ratio of 550 to 700 moles of sorbitol: 1 mole of protein, and molar ratio of PEG to protein is 2–50:1. Composition additionally contains a buffer. Composition in lyophilised form is stable for at least 4 years at 2–8 °C.
EFFECT: also disclosed is a method for preparing said composition and pharmaceutical composition containing same.
24 cl, 23 tbl, 11 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS USED FOR STABILISATION OF PROTEIN-CONTAINING FINISHED FORMS | 2011 |
|
RU2584232C2 |
| PHARMACEUTICAL COMPOSITIONS OF HER2 ANTIBODY CONJUGATE | 2020 |
|
RU2795196C2 |
| COMPOSITIONS CONTAINING ANTIBODY-DRUG CONJUGATES DUOCARMICIN | 2016 |
|
RU2687237C1 |
| HIGHLY CONCENTRATED COMPOSITIONS OF MONOCLONAL ANTIBODIES | 2013 |
|
RU2711089C2 |
| STABLE ISOTONIC LYOPHILIZED PROTEIN COMPOSITION | 1996 |
|
RU2229288C2 |
| COMPOSITION CONTAINING ANTI-PD-1/HER2 BISPECIFIC ANTIBODY, METHOD FOR PREPARATION AND USE THEREOF | 2020 |
|
RU2829156C2 |
| STABLE ISOTONIC LYOPHILISED PROTEIN COMPOSITION | 1996 |
|
RU2497500C2 |
| COMPOSITIONS OF ANTIBODIES | 2005 |
|
RU2426554C2 |
| HIGHLY CONCENTRATED COMPOSITIONS OF ANTIBODIES AND PROTEINS | 2004 |
|
RU2332986C2 |
| HIGHLY CONCENTRATED FORMULATIONS OF MONOCLONAL ANTIBODIES | 2013 |
|
RU2827884C2 |
